VPT:CC - The 2023 Year in Review

(TheNewswire)

Toronto, Ontario – TheNewswire - January 29, 2024 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), ( TSXV:VPT ) ( OTC:VPTDF ) is pleased to provide 2023 inReview from the Ventripoint CEO and President, Dr. Alvira Macanovic.

Dear Shareholders:

I have now completed my first year as CEO andPresident. I’m happy to report that we had an extremely productiveyear at Ventripoint in 2023, with our amazing team meeting manymilestones and garnering more attention for Ventripoint than in thehistory of the company.

It has been an honor leading this company into the nextphase of its transformation and showing everyone what can beaccomplished with the right people and plan.  It has been a historicyear for Ventripoint.  Our aim to be the standard of care in imagingthe heart with Artificial Intelligence is on course, and the journeyhas just begun!

Before I cover some of our important milestones,however, I’d like to share an incredible moment that demonstrates the extraordinary power of our A.I.technology to add a new capacity to the global healthcare system.

In Nov. 2023, our clinical applications and sales teamhad an evaluation at the Motol University Hospital in the CzechRepublic. That’s the only pediatric cardiac center in the country.The staff immediately put Ventripoint into action — using it to scanthe heart of a 30-minute newborn that has a ventricular septal defect. The baby was literally brought from the delivery room (still gooeyas described by the team) to our team. I think this may be theyoungest baby our technology has ever been used on.

Now that's elevating cardiac care with A.I. You can seethis amazing moment here.

Now, let me tell you about some of our otheraccomplishments:

Partnerships & Sales

• We signed a global distribution and marketingpartnership with ASCEND, one of theworld’s largest providers of cardiac health care technologies.ASCEND is trusted by AGFA Healthcare, Sectra, Oracle/ Cerner, andother major players in the healthcare system. Its technology stack hasbeen integrated into the workflows of 1,000+ top-ranked healthcarefacilities and 600+ health systems, representing a user base of 50,000who serve millions of heart patients. To be represented by them is anoutstanding accomplishment by the team and bodes well for2024!

• One of the United States’ most respected foundations,the Ollie Hinkle Heart Foundation, has also selected us as one ofthree technologies they are promoting to US hospitals they work with.The OHHF has called Ventripoint “a game-changerfor children with heart disease”. OHHF has committed to bringingtogether 13 U.S. hospital partners into its Take Heart program, with30 more expected to join, to promote new technologies and patient careapproaches to heart health care, particularly for children and theirfamilies. They have told me they will be making Ventripoint front andcenter.

“We want tointroduce Ventripoint to all our hospital partners, to make it astandard of care,” — Beth Rumack, Ollie Hinkle HeartFoundation .

• In the UK, Ventripoint is being used by the EvelinaLondon Children’s Hospital (part of Guy's and St Thomas' NHSFoundation Trust). This is significant because it is a specialist NHShospital, the second largest provider of children’s services inLondon, caring for children and young people across south London andsoutheast England. The Children’s Heart Services (cardiology) caresfor around 6,000 patients each year.

• We’ve also made significant advances In Germany, withtwo major purchases:

• • The Deutsches Herzzentrum der Charité (DHZC) GermanHeart Center in Berlin also purchased our system. Prof. Felix Berger,Director of the Clinic for Congenital Heart Disease — PediatricCardiology — at the hospital, said Ventripoint’s AI system offersa way to get “important data on the function of the heart muscle.This allows us to plan therapy even more precisely, check it anytime,and adjust it if necessary.” The DHZC is the university heart centerof Charité– Universitätsmediz, one of Germany’s mostresearch-intensive medical institutions, which was ranked this year asthe 7th best hospital in the world and the best in Europe byNewsweek.

• • Our VMS+ was purchased by the Freiburg Hospital.Located in Breisgau, Germany, Freiburg’s University Medical Centreis one of the largest hospitals in Europe and is recognized as thesupra-regional center for the treatment of complicated heart disease.It treats approximately 90,000 inpatients and 897,000 outpatientsannually.

Continuing A.I. Innovations

"VMS+ notonly gives us a very precise spatial view of complex congenitalmalformations at any time, but it also provides us with important dataon the function of the heart muscle. This allows us to plan therapyeven more precisely, check it at any time, and adjust it ifnecessary,” — Prof. Felix Berger, Director of the Clinic forCongenital Heart Disease, Pediatric Cardiology at DHZC

• The next version of our technology — VMS+ 4.0 — ison schedule and is expected to be on the market in the second quarterof 2024. This is a major update — our unit will be even simpler touse and the A.I. will be able to automatically model out the parts ofthe heart cardiologists want to see. It’s also a much-neededinnovation for the healthcare system. Thanks to our use of A.I.,Ventripoint will save healthcare workers time, ensure exams “justwork” with high accuracy, and relieve the expense and pressurecurrently put on MRI teams, not to mention patients who now won’tneed to spend hours preparing.

• We are also well on our way to having the ability toshow “living heart” models of the heart functioning in 4D. Thismeans that cardiologists, other caregivers — and even patients —will soon have actual models showing ventricles in action, blood flow,and other aspects. What’s exciting here, and I believe will makeVentripoint of great interest to physicians, is that these “livingheart” images can be taken in minutes using ultrasoundequipment.

Increasing Awareness

“ Our aim is that byworking together, we can ultimately provide reliable and effectivetools for clinicians on a global scale,” — Jeffrey Soble, MD, CEOASCEND.

• We’ve been getting media attention, too. TheVentripoint story was broadcast across the United Kingdom by the ITV network, as a part of a specialon breakthroughs in heart technology. That broadcast was also endorsedby the British Heart Foundation, which continues to show it on theirwebsite. You can see .

• We are also getting more attention in Canada, whereVentripoint is already in a number of hospitals. Canada Health Watch,whose readership are highly discriminating health care professionalsand administrators, featured our latest white paper in January. They also wrote a lengthy story for theiraudience that you can read here.

• We’ve also been a major presence at internationalconferences, to accelerate brand awareness and connect with potentialpartners and investors.  These include theBritish Congenital Cardiac Association Annual Conference in Bristol;the British Society of Echocardiography’s annual conference; the51st Annual Nordic Paediatric Cardiology Meeting in Helsinki, hostedby the Finnish Cardiac Society; the 8th Annual Paediatric Echo SocietySymposium in Orlando; the 8th World Congress of Paediatric Cardiologyand Cardiac Surgery in Washington, DC. and the Advanced Imaging 2023Pericardial Disease conference, sponsored by the British Society ofEchocardiography and the Royal Society of Medicine.

• On May 30, our team also obtained European UnionMedical Device Regulation (EU MDR) certification for our cardiacdiagnostic system. This is an important milestone as we further expandour presence in Europe.  By receiving EU MDR certification,Ventripoint Diagnostics has shown it can meet the rigorous regulatorylandscape in Europe and can be accepted into hospitals.

" Having had experiencewith the older Ventripoint system, the new VMS + system with itsincreased functionality is a great addition to our echo lab,” —Dr. Saleha Kabir, Lead Physiologist in Paediatrics and AdvancedEchocardiography

When you read all of the above, I hope you find theseencouraging signs of the company’s direction and futuregrowth.

For 2024, I can tell you that we are now concentratingon making Ventripoint a well-known brand in the world’s hospitals.Our partnerships with ASCEND and others will help that happen — butso will the constant improvements of our technology and A.I. Also, wewill be bolstering our sales and communication teams throughout theyear.

Ventripoint is now being recognized as one ofCanada’s true success stories in healthcare innovation. As the OllieHinkle Heart Foundation said, we are a “game changer”. We areliterally putting our hearts into A.I. — to improve our healthcaresystem and save lives.

Regards,

Dr. Alvira Macanovic

CEO & President

Ventripoint Diagnostics

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.

For further information, pleasecontact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2024 TheNewswire - All rights reserved.